RANI Stock Risk & Deep Value Analysis
Rani Therapeutics Holdings Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About RANI Stock
We analyzed Rani Therapeutics Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RANI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RANI Risk Analysis & Red Flags
What Could Go Wrong
Despite the extended cash runway until Q4 2027, Rani Therapeutics is still a clinical-stage company burning significant cash. Success is highly dependent on positive clinical trial outcomes and the ability to secure major partnerships or additional funding without excessive dilution. Failure in key trials, or an inability to attract a partner, could lead to a rapid depletion of cash, necessitating further highly dilutive capital raises or even potential bankruptcy before commercialization.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Continued heavy cash burn exceeding current cash runway projections
- ⚠
Significant dilution from the recent private placement with minimal revenue to offset
- ⚠
Consistent earnings misses and lack of clear profitability timeline
- ⚠
No major strategic partnerships announced despite advanced technology
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for RT-102 or RT-105
- 📅
Further significant equity dilution without substantial clinical progress or partnerships
- 📅
Increased competitive pressure from alternative oral biologics delivery technologies
When to Reconsider
- 🚪
Failure of RT-102 or RT-105 to meet primary endpoints in clinical trials
- 🚪
Cash runway falls below 12 months without clear plans for additional non-dilutive funding or partnerships
- 🚪
Stock price drops below $0.50 and stays there for consecutive weeks, signaling a loss of investor confidence
Unlock RANI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Rani Therapeutics Holdings Inc (RANI) Do?
Market Cap
$110.07M
Sector
Healthcare
Industry
Biotechnology
Employees
105
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Visit Rani Therapeutics Holdings Inc WebsiteInvestment Thesis
Rani Therapeutics is a high-risk, high-reward investment focused on its transformative RaniPill platform, which could revolutionize biologics delivery by enabling oral administration. The recent $60.3M capital infusion provides crucial runway to advance its promising pipeline. If the company successfully navigates clinical trials and secures strategic partnerships, it has the potential to capture a significant share of the massive biologics market, leading to a substantial re-rating of its stock and achieving 10x growth within 3-5 years.
Is RANI Stock Undervalued?
Unlock the full AI analysis for RANI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RANI Price Targets & Strategy
12-Month Target
$7.80
Bull Case
$11.00
Bear Case
$0.50
Valuation Basis
Based on median analyst price target reflecting future pipeline value, commercialization potential, and successful clinical milestones.
Entry Strategy
Dollar-cost average at current levels and on any dips towards $0.70-$0.80, leveraging the extended cash runway for a longer-term investment horizon.
Exit Strategy
Take profit on significant clinical news or partnership announcements, with initial targets at $5-$7; re-evaluate above $7.80. Implement a stop-loss if cash runway concerns re-emerge or if RT-102 Phase 1 data is negative.
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RANI Financially Healthy?
Valuation
P/E Ratio
-1.59
PEG Ratio
-0.03
Price/Book
-6.60
Price/Sales
30.50
Profitability
Operating Margin
-1293.57%
Net Margin
-1075.87%
Return on Equity
-31.22%
EPS
$-0.59
Balance Sheet
Current Ratio
4.21
Quick Ratio
4.08
Other
Beta (Volatility)
0.82
Does RANI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat's durability relies heavily on continued innovation, successful patent defense, and the ability to rapidly advance and commercialize pipeline candidates before competitors develop similar or superior oral delivery mechanisms.
Moat Erosion Risks
- •Intellectual property challenges or expiration of key patents
- •Clinical trial failures that render the technology less viable or effective
- •Emergence of a more cost-effective or easier-to-manufacture oral biologics delivery system from competitors
RANI Competitive Moat Analysis
Sign up to see competitive advantages
RANI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - The groundbreaking technology attracts bullish retail interest, but the significant financial risks and early stage lead to cautious sentiment.
Institutional Sentiment
Positive - Evidenced by a 'Moderate Buy' consensus from analysts (5 Buy, 1 Sell) and a median price target significantly above current levels. Recent analyst actions include both initiations and adjustments.
Insider Activity (Form 4)
No specific Form 4 filings reported for buys/sells in the last 90 days. No CEO/CFO activity flagged.
Options Flow
Normal options activity - No specific unusual options activity or significant put/call ratio skew reported in the provided data.
Earnings Intelligence
Next Earnings
2026-05-13
Surprise Probability
Medium-Low
Historical Earnings Pattern
Given the early stage and focus on R&D, earnings reactions are highly volatile and sensitive to cash position updates and clinical progress rather than traditional profitability metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A - Rani's RaniPill platform is a unique oral delivery mechanism. While other companies (e.g., Entera Bio, Oramed) work on oral biologics, their approaches differ significantly, making a direct 'best-in-class' comparison difficult for the specific mechanism.
Market Share Trend
Not yet applicable, as the company is pre-commercial and focused on clinical development.
Valuation vs Peers
Trading at a significant discount based on current market cap relative to its potential TAM, but at an infinite premium on traditional profitability metrics due to negative earnings. Valuation is driven entirely by future pipeline success and commercialization potential, not current financials.
Competitive Advantages
- •Proprietary and patented RaniPill technology for oral delivery of large molecule biologics
- •Potential for superior patient adherence due to non-injectable route
- •Broad applicability across various therapeutic areas (e.g., osteoporosis, psoriatic arthritis)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RANI Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on May 13, 2026, with updates on cash runway and clinical progress
- •Further updates on RT-102 Phase 1 osteoporosis clinical trial
- •Strategic input and guidance from newly appointed advisor Dr. Sara Kenkare-Mitra
Medium-Term (6-18 months)
- •Advancement of RT-102 into Phase 2/3 clinical trials
- •Preclinical data readouts and initiation of Phase 1 for RT-105 (psoriatic arthritis)
- •Announcement of strategic partnerships or licensing agreements for RaniPill platform
Long-Term (18+ months)
- •Commercialization of RaniPill platform through internal development or licensing deals
- •Expansion of pipeline to address broader range of biologics
- •Establishing market leadership in oral biologics delivery
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RANI?
- ✓
Successful progression of RT-102 and RT-105 through clinical trial phases
- ✓
Announcement of any material licensing or development agreements with pharmaceutical majors
- ✓
Acceleration in revenue (if any) or significant reduction in cash burn
Bull Case Analysis
See what could go right with Premium
Competing with RANI
See how Rani Therapeutics Holdings Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Rani Therapeutics Holdings Inc RANI | $110.1M | 7.0 | -1.6 | $1.5M | -1075.9% | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Rani Therapeutics Holdings Inc Makes Money
Rani Therapeutics is a biopharmaceutical company that designs and develops an innovative drug delivery platform called RaniPill. This technology aims to replace traditional injectable biologics (large molecule drugs) with an oral capsule. The RaniPill is designed to safely pass through the stomach and then self-administer a drug via a tiny, painless, self-dissolving micro-needle directly into the intestinal wall for absorption. The company's business model is centered on advancing its pipeline of RaniPill-enabled drug candidates through clinical development and then either licensing its platform technology to larger pharmaceutical companies or commercializing select drug programs itself, generating revenue through upfront payments, milestone payments, and royalties or product sales.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Rani Therapeutics Holdings Inc (RANI)?
As of April 29, 2026, Rani Therapeutics Holdings Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Rani Therapeutics Holdings Inc?
Rani Therapeutics Holdings Inc's market capitalization is approximately $110.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Rani Therapeutics Holdings Inc use?
RANI is the ticker symbol for Rani Therapeutics Holdings Inc. The company trades on the NGM.
What is the risk level for RANI stock?
Our analysis rates Rani Therapeutics Holdings Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RANI?
Rani Therapeutics Holdings Inc currently has a price-to-earnings (P/E) ratio of -1.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is RANI stock profitable?
Rani Therapeutics Holdings Inc has a profit margin of -1075.9%. The company is currently unprofitable.
How often is the RANI DVR analysis updated?
Our AI-powered analysis of Rani Therapeutics Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RANI (Rani Therapeutics Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.